RCS - N4 Pharma PLC - New Corporate Presentation

N4 PharmaAnnouncement

24/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241024:nRSX3814Ja&default-theme=true

RNS Number : 3814J  N4 Pharma PLC  24 October 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

New Corporate Presentation and CEO Q&A

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce the publication of a new corporate presentation
accompanied by a video update from CEO, Nigel Theobald.

 

Key points covered in the presentation include N4 Pharma's strategic focus on
two key lead programs: N4 101 for Irritable Bowel Disease ("IBD") and ECP 105
for post-surgical scarring prevention, utilising the Company's proprietary
delivery technologies, Nuvec® and LipTide™. The Company's aim is to advance
preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") /
Investigational New Drug ("IND") filing in the coming years, while also
pursuing licensing and platform collaboration opportunities.

 

Investors are invited to submit questions on the presentation via N4 Pharma's
investor hub, and CEO Nigel Theobald will address these in a subsequent video.
Register and submit questions at: https://investors.n4pharma.com/link/MP7A7e
(https://investors.n4pharma.com/link/MP7A7e) .

 

The full slide deck is available to view on N4 Pharma's investor hub here:
https://investors.n4pharma.com/s/01e7a3
(https://investors.n4pharma.com/s/01e7a3)

 

 

 

For more information please contact:

 

 N4 Pharma plc                                                Via N4 Pharma Investor Hub

 Nigel Theobald, CEO                                          https://investors.n4pharma.com/announcements

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 Investor hub                                                 Sign up at investors.n4pharma.com (http://investors.n4pharma.com)

 Engage with us directly at N4 Pharma Investor Hub

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing unique nucleic acid
based products using its patented delivery systems Nuvec® and Liptide®. Its
first two products are an oral anti-inflammatory product for IBD and an siRNA
to knock down MRTF-B  which reduces scarring post Glaucoma surgery. As well
as these it is looking to develop further oncology and gene therapy products.

 

Its novel delivery systems are also available to third parties for licensing
to develop their own products in oncology, gene therapy and vaccines for
upfront payments, milestone payments and ultimately royalty payments once
products reach the market.

 

It is also seeking partners or investors to take its initial products into
phase 1 clinical trials.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAMJBPTMTTTBAI